BioCryst Pharmaceuticals (BCRX) Reports Next Week: Wall Street Expects Earnings Growth

Core Viewpoint - BioCryst Pharmaceuticals (BCRX) is anticipated to report a year-over-year increase in earnings and revenues for the quarter ended June 2025, with the actual results having a significant impact on its near-term stock price [1][2]. Financial Expectations - The upcoming earnings report is expected to show quarterly earnings of $0.03 per share, reflecting a year-over-year increase of 150% [3]. - Revenues are projected to be $148.85 million, which is a 36.2% increase from the same quarter last year [3]. Estimate Revisions - The consensus EPS estimate has remained unchanged over the last 30 days, indicating that analysts have not significantly reassessed their initial estimates [4]. - For BioCryst, the Most Accurate Estimate is lower than the Zacks Consensus Estimate, resulting in an Earnings ESP of -66.67%, suggesting a bearish outlook from analysts [11]. Earnings Surprise History - In the last reported quarter, BioCryst was expected to post a loss of $0.07 per share but instead delivered break-even earnings, resulting in a surprise of +100.00% [12]. - Over the past four quarters, the company has beaten consensus EPS estimates two times [13]. Industry Comparison - In the Zacks Medical - Drugs industry, Indivior PLC (INDV) is expected to report earnings of $0.26 per share for the same quarter, indicating a year-over-year decline of 40.9% [17]. - Indivior's revenue is projected to be $244.27 million, down 18.3% from the previous year, but it has an Earnings ESP of +11.54%, suggesting a likelihood of beating the consensus EPS estimate [18][19].